Haemolytic uraemic syndrome: therapeutic effect of plasma infusion

ROCCO MISIANI, ALDO CLARIS APPIANI, ALBERTO EDEFONTI, ELIANA GOTTI, ALBERTO BETTINELLI, MARISA GIANI, EDOARDO ROSSI, GIUSEPPE REMUZZI, GIULIANO MECCA

Abstract

The therapeutic effect of plasma infusion was evaluated in 10 children and seven adults with haemolytic uraemic syndrome. All but one patient responded to this treatment with rapid disappearance of haematological abnormalities. The patient who apparently failed to respond to plasma infusion obtained complete remission of the disease after plasmapheresis. Although 15 of the 17 patients were anuric or oliguric on admission, renal function recovered completely in eight children and two adults. Seven patients showed residual chronic renal failure and two required long-term maintenance haemodialysis. Treatment with plasma was also successful in patients with relapses or recurrent episodes.

Plasma infusion is a promising therapeutic approach for the haemolytic uraemic syndrome and deserves further study in clinical trials.

Introduction

Haemolytic uraemic syndrome is characterised by microangiopathic haemolytic anaemia, thrombocytopenia, and renal failure. Histological examination shows thrombotic occlusions in the microcirculation, the kidney being the main target organ. The pathogenesis has been ascribed to localised intravascular coagulation,\(^1\)-\(^3\) and heparin\(^4\) and fibrinolytic agents\(^5\)-\(^7\) have been used. Studies of platelet survival and fibrinogen turnover, however, have indicated that intravascular platelet aggregation is an important step in the pathogenesis,\(^8\)\(^-\)\(^10\) thus supporting the use of antplatelet agents.\(^8\)\(^-\)\(^10\) As yet none of these treatments has proved entirely effective.

The haemolytic uraemic syndrome shares many characteristics with thrombotic thrombocytopenic purpura, and similar pathophysiological mechanisms are suspected for both diseases.\(^11\) Some reports have drawn attention to the beneficial effect of exchange transfusion and plasmapheresis in thrombotic thrombocytopenic purpura,\(^15\)-\(^15\) and Bukowski et al have suggested that these procedures may act by removing antibodies, immune complexes, or other undefined toxic substances.\(^15\) Remission in a patient with thrombotic thrombocytopenic purpura using plasma infusion alone,\(^16\) however, suggested that the infusion replaced a missing factor, possibly a physiological inhibitor of platelet aggregation. This suggestion received support from studies\(^17\)-\(^22\) indicating that plasma from patients with thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome lacks a factor which normally stimulates the release of vascular prostacyclin (PGI\(_2\)). In some of these patients infusions of normal plasma corrected the plasma factor defect and induced remission. We report here the results of treatment with plasma infusion in 17 patients with haemolytic uraemic syndrome.

Patients and methods

We studied 10 children aged 9 months to 8 years and seven adults (aged 14 to 61 years) admitted to hospital over two years. The diagnosis of haemolytic uraemic syndrome was based on the classic findings of microangiopathic haemolytic anaemia, thrombocytopenia, and renal failure. Microangiopathic haemolytic anaemia was defined as a drop in reticulocyte count and evidence of schistocytosis in the peripheral blood film. Renal biopsy was performed in 14 patients. Histological examination by immunofluorescence and light microscopy confirmed the diagnosis of haemolytic uraemic syndrome in all cases.

To evaluate the effect of treatment the following criteria were adopted: haematological response—increased platelet count or reduced signs of microangiopathic haemolytic anaemia (decreased serum lactate dehydrogenase and number of fragmented red blood cells, increased serum haptoglobin), or both; haematological remission—return of the platelet count to normal (150 x 10\(^9\)/L) and disappearance of all signs of microangiopathic haemolytic anaemia; renal response—improved renal function and reduced urinary abnormalities; and complete remission—correction of all haematological and renal abnormalities.

All patients were treated with plasma infusion according to the following schedule. During the first session of haemodialysis or over eight hours in patients not undergoing dialysis, we administered a loading dose (30 to 40 ml/kg) of fresh-frozen plasma; then a plasma infusion of 15 to 20 ml/kg was given daily until haematological remission occurred. The same schedule of treatment was used for early relapses and recurrent episodes. Plasmapheresis was used in one patient (case 10) who did not appear to benefit from plasma infusion. This patient was treated by exchanging 40 ml/kg of her plasma for fresh-frozen plasma on alternate days until haematological remission was achieved. Whole blood or packed red blood cells were given when the packed cell volume was below 0.25. Fourteen patients needed haemodialysis.

Four patients received antihypertensive drugs: atenolol, prazosin, dihydralazine, clonidine, frusemide, and nifedipine.

Results

Clinical and laboratory data on admission are shown in table I. All patients had thrombocytopenia and microangiopathic haemolytic anaemia, in most cases severely. Eleven patients were anuric, four oliguric, and two had non-oliguric renal insufficiency. The mean duration of oliguria or anuria in patients who recovered their renal function was 20 days (range 10-37). Microscopical haematuria and proteinuria were found in all non-anuric patients. The results of coagulation tests, including prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen concentration, and fibrinogen-fibrin degradation products, were normal in all cases.

After plasma infusion a haematological response was noted within...
TABLE I—Clinical and laboratory findings on admission

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age</th>
<th>Sex</th>
<th>Prodromal illness</th>
<th>Blood pressure (mm Hg)</th>
<th>Urine output (ml/m²/day)</th>
<th>Packed cell volume (x 10¹²/l)</th>
<th>Platelets (x 10¹¹/l)</th>
<th>Haemoglobin (g/l)</th>
<th>Blood urea nitrogen (mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16 mth</td>
<td>F</td>
<td>Diarrhoea</td>
<td>160/110</td>
<td>&lt;200</td>
<td>0.28</td>
<td>20</td>
<td>0.5</td>
<td>38.6</td>
</tr>
<tr>
<td>2</td>
<td>28 mth</td>
<td>F</td>
<td>Diarrhoea</td>
<td>200/140</td>
<td>None</td>
<td>0.9</td>
<td>15</td>
<td>&lt;0.2</td>
<td>32.1</td>
</tr>
<tr>
<td>3</td>
<td>31 mth</td>
<td>M</td>
<td>Respiratory tract infection</td>
<td>100/110</td>
<td>None</td>
<td>0.19</td>
<td>60</td>
<td>0.63</td>
<td>42.1</td>
</tr>
<tr>
<td>4</td>
<td>35 mth</td>
<td>M</td>
<td>Diarrhoea</td>
<td>120/70</td>
<td>None</td>
<td>0.21</td>
<td>40</td>
<td>0.2</td>
<td>19.6</td>
</tr>
<tr>
<td>5</td>
<td>32 mth</td>
<td>M</td>
<td>Diarrhoea</td>
<td>120/80</td>
<td>&lt;200</td>
<td>0.11</td>
<td>110</td>
<td>&lt;0.2</td>
<td>77.8</td>
</tr>
<tr>
<td>6</td>
<td>55 mth</td>
<td>M</td>
<td>Diarrhoea</td>
<td>110/80</td>
<td>None</td>
<td>0.25</td>
<td>11</td>
<td>&lt;0.2</td>
<td>39.3</td>
</tr>
<tr>
<td>7</td>
<td>9 mth</td>
<td>M</td>
<td>Diarrhoea</td>
<td>100/60</td>
<td>None</td>
<td>0.22</td>
<td>40</td>
<td>0.2</td>
<td>17.1</td>
</tr>
<tr>
<td>8</td>
<td>46 mth</td>
<td>F</td>
<td>Vomiting</td>
<td>100/60</td>
<td>None</td>
<td>0.20</td>
<td>36</td>
<td>&lt;0.2</td>
<td>21.4</td>
</tr>
<tr>
<td>9</td>
<td>8 yr</td>
<td>M</td>
<td>Vomiting</td>
<td>110/70</td>
<td>1500</td>
<td>0.18</td>
<td>50</td>
<td>&lt;0.2</td>
<td>39.3</td>
</tr>
<tr>
<td>10</td>
<td>8 yr</td>
<td>F</td>
<td>Diarrhoea</td>
<td>110/90</td>
<td>None</td>
<td>0.18</td>
<td>25</td>
<td>&lt;0.2</td>
<td>21.4</td>
</tr>
<tr>
<td>11</td>
<td>23 yr</td>
<td>M</td>
<td>None</td>
<td>120/70</td>
<td>700</td>
<td>0.25</td>
<td>20</td>
<td>&lt;0.2</td>
<td>16.4</td>
</tr>
<tr>
<td>12</td>
<td>41 yr</td>
<td>M</td>
<td>None</td>
<td>200/150</td>
<td>None</td>
<td>0.27</td>
<td>10</td>
<td>&lt;0.2</td>
<td>39.3</td>
</tr>
<tr>
<td>13</td>
<td>14 yr</td>
<td>M</td>
<td>None</td>
<td>180/90</td>
<td>None</td>
<td>0.22</td>
<td>80</td>
<td>&lt;0.2</td>
<td>22.1</td>
</tr>
<tr>
<td>14</td>
<td>32 yr</td>
<td>F</td>
<td>Vomiting</td>
<td>240/150</td>
<td>None</td>
<td>0.22</td>
<td>85</td>
<td>&lt;0.2</td>
<td>42.5</td>
</tr>
<tr>
<td>15</td>
<td>61 yr</td>
<td>M</td>
<td>None</td>
<td>170/100</td>
<td>None</td>
<td>0.23</td>
<td>80</td>
<td>&lt;0.2</td>
<td>22.8</td>
</tr>
<tr>
<td>16</td>
<td>22 yr</td>
<td>M</td>
<td>None</td>
<td>220/120</td>
<td>None</td>
<td>0.23</td>
<td>87</td>
<td>&lt;0.2</td>
<td>39.3</td>
</tr>
<tr>
<td>17</td>
<td>30 yr</td>
<td>M</td>
<td>None</td>
<td>210/130</td>
<td>&lt;200</td>
<td>0.30</td>
<td>121</td>
<td>&lt;0.2</td>
<td>26.1</td>
</tr>
</tbody>
</table>

Conversion: SI to traditional units—Blood urea nitrogen: 1 mmol/l = 2.8 mg/100 ml.

TABLE II—Platelet count before and after plasma infusion in 17 patients with haemolytic uraemic syndrome

<table>
<thead>
<tr>
<th>Case No</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets (x 10¹¹/l): At admission</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After 3 days of plasma infusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conversion: SI to traditional units—Blood urea nitrogen: 1 mmol/l = 2.8 mg/100 ml.

Discussion

Plasma infusion has recently been proposed as a valuable form of treatment in thrombotic thrombocytopenic purpura. A preliminary report described two patients affected by haemolytic uraemic syndrome who responded to plasmapheresis and plasma infusion with improvement of haematological abnormalities and in one case with partial recovery of renal function. Our series of patients with haemolytic uraemic syndrome included 10 children and seven adults treated only with plasma infusion and supportive measures. A beneficial effect was observed in all but one case. The patient who failed to respond to plasma infusion recovered rapidly and completely after plasmapheresis.

Haemolytic uraemic syndrome in children is often described as a self-limiting form of the syndrome, usually with complete recovery, but anuria or prolonged oliguria has been associated with poor chances of survival and restoration of normal renal function. Gianantonio et al reported 25% mortality among patients with oliguria of more than 25 days' duration compared with an overall mortality of 6%. The incidence of residual chronic renal insufficiency in patients with oliguria and anuria varies from 17% to 52% in different series. Although nine of the 10 children in our series were anuric or oliguric, no child died or needed long-term haemodialysis. Two children still showed mild to moderate renal insufficiency after six months of follow-up.

Haemolytic uraemic syndrome in adults is generally severe, and recovery of renal function is uncommon. In a series recently reported by Morel-Maroger et al 50% of the patients died and 20% developed chronic renal failure requiring long-term haemodialysis. In our series all adults treated with plasma infusion obtained prompt haematological remission. In hypertensive patients blood pressure fell, making it possible to reduce their antihypertensive treatment. Normal blood pressure and platelet count seem to be of great importance,
since several patients, particularly in the acute phase of the disease, die because of hypertensive or haemorrhagic complications. Two of our adult patients, whose renal biopsies showed pronounced arterial and arteriolar lesions, remained anuric and required long-term haemodialysis. In two others renal function recovered completely, whereas the remaining three adults had residual renal insufficiency.

A close temporal relationship was noted between plasma infusion and improvement of haematological values in all patients who benefited from the treatment. Previous studies had reported that the platelet count returned to normal after one to 23 days (mean nine days), depending on the severity of the initial thrombocytopenia.14 17 Thrombocytopenia responded to the treatment more rapidly in our patients, who showed a normal platelet count after one to eight days (mean three days). The effectiveness of plasma infusion was particularly evident in one patient who repeatedly relapsed as soon as plasma infusion was stopped and promptly responded once treatment was restarted (fig 2).

FIG 2 — Case 3. Changes in platelet count and haptoglobin and serum creatinine concentrations, showing temporal relation between changes in these values and infusions of plasma.

A likely explanation for the effectiveness of plasma infusion is that some deficiency in a normal plasma component plays a part in the pathogenetic sequence leading to thrombotic microangiopathy.23 Several studies have suggested that the missing factor might be the physiological stimulator of vascular prostacyclin.17 19 20 24 In patients who do not respond promptly to infusion the exchange procedure has the advantage of removing from the circulation aetiologic factors and other material such as damaged red blood cell membranes and the products of platelet and white cell secretion. Careful clinical trials are warranted to establish the value of plasma infusion compared with other forms of treatment in haemolytic uremic syndrome.

This study was supported by Associazione Bergamasca per lo Studio delle Malattie Renali and the Italian National Research Council. We thank Dr M B Donati and Dr G de Gaetano for critically reviewing the manuscript and Dr T Bertani for examining renal biopsy specimens.

Requests for reprints should be addressed to: Dr Giuseppe Remuzzi, Division of Nephrology, Ospedali Riuniti di Bergamo, 24100 Bergamo, Italy.

References

(Accepted 5 August 1982)

Correction

Are HLA antigens important in the development of alcohol-induced liver disease?

Two errors occurred in this paper by R Faizallah et al (21 August, p 533). In the second paragraph of the Subjects and method the second sentence should have read: "Tests for the presence of hepatitis B surface antigen (HBsAg) and hepatitis B cored antibody (HBCAb) were carried out in most cases." In the Results the last sentence should have read: "HBCAb was absent in the patients for whom only two were positive for HBCAb (by countercurrent immunoelectrophoresis). . . ."